Compare Ryanair Holdings plc (RYAAY) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ryanair Holdings plc vs Sana Biotechnology Inc — how do they compare? Ryanair Holdings plc trades at $54.24 (market cap $27.11B), while Sana Biotechnology Inc trades at $2.79 (market cap $836.71M). The key difference: Ryanair Holdings plc is far larger — about 32.4× Sana Biotechnology Inc's market cap, and Ryanair Holdings plc pays a 1.66% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ryanair Holdings plc for 72 Days and Sana Biotechnology Inc for 23 Days on average.
| RYAAY | SANA | |
|---|---|---|
Market Cap | $27.11B | $836.71M |
Volume | 2,427,380 | 4,507,444 |
Sector | Industrials | Health |
52-Week High | $73.82 | $5.92 |
52-Week Low | $51.95 | $2.68 |
Typical Hold Time | 72 Days | 23 Days |
Enterprise Value | $24.18B | $749.96M |
Dividend Yield | 1.66% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RYAAY trades at $54.04, down 3.5% on the day, with a bearish technical signal from moving averages. The company reported revenue of $13.95 billion in 2025 and net income of $1.61 billion, with a P/E ratio of 13.43. Recent earnings have been mixed, with a miss in Q2 2026. News highlights include CEO commentary on Boeing MAX 10 delays and concerns over fuel costs impacting future airfares.
The stock presents a valuation opportunity with low P/E and EV/EBITDA multiples, but faces near-term headwinds from volatile fuel prices and reduced traffic forecasts. Analyst consensus is moderately bullish, with 65% buy ratings, though technical indicators suggest caution. Key risks include oil price sensitivity and competitive pressures in the European airline sector.
SANA Biotechnology trades at $2.79, up 2.57% today, but faces significant fundamental challenges with no revenue, negative EBITDA of -$192.96M, and deeply negative ROE of -152.87%. Technical indicators show bearish momentum with moving averages signaling sell pressure, though oscillators remain neutral. The company continues to burn cash with -$55.33M net cash flow in 2025, relying on financing activities to fund operations while advancing its cell therapy pipeline through multiple investor presentations.
Despite 82% analyst buy ratings and a $9.50 consensus price target, SANA represents a high-risk biotech investment with substantial execution risk. The absence of revenue, persistent losses, and cash burn require careful monitoring of clinical milestones. Near-term catalysts depend on pipeline progress, but shareholders face dilution risk from continued financing needs amid challenging technical conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Ryanair Holdings plc
Ryanair is the leading airline group by passenger numbers in Europe. The company employs a low-cost no-frills model to offer low fares to leisure customers on short-haul intra-European routes. In 2020, the most recent pre-pandemic fiscal year, the company carried 149 million passengers, utilizing a fleet of 467 Boeing 737 aircraft across its 1,800 routes. To keep costs low the company serves predominantly lower-cost secondary airports. The company generated sales of EUR 8.5 billion in fiscal 2020.
Read more on RYAAY →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
